David Matly

Mr. Matly brings extensive commercial launch and leadership experience across both orphan diseases and oncology. Mr. Matly joins them from Novartis where he served as the global Vice President of the MDS/AML franchise, one of the largest potential growth areas of Novartis Oncology, leading the launch preparation of their flagship program, as well as ensuring the commercial success of the entire AML/MDS portfolio. Before this role, Mr. Matly was the global commercial lead of the sickle cell disease therapeutic area, leading the launch of ADAKVEO, which at the time was the first approved novel therapy in almost two decades. Also at Novartis, Mr. Matly was the global commercial lead of PROMACTA/REVOLADE, the largest growth driver of Novartis Oncology. Mr. Matly began his career at Eli Lilly, holding several positions of increasing responsibility in sales and marketing, most notably leading the US launch of CYRAMZA in metastatic lung cancer.

Mr. Matly received his B.S. in Industrial Engineering from Purdue University and his M.B.A. from Harvard Business School.